Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.59 |
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545720 | 0.90 | TACR1 (0.51) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL11306116 | 0.85 | TACR1 (0.63) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL6301053 | 0.83 | MTOR (0.58) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL4874599 | 0.83 | MTOR (0.58) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL5670867 | 0.83 | CCR1 (0.48) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL30661718 | 0.82 | MLYCD (0.65) | MLYCD | |
| SCHEMBL1695141 | 0.81 | MTOR (0.58) | MTOR | |
| SCHEMBL2341110 | 0.81 | LMNA (0.47) | TACR1 | |
| SCHEMBL25779257 | 0.80 | MTOR (0.55) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL15844016 | 0.80 | TACR1 (0.58) | TACR1MTORMLYCDP2RX1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-109053742-B | Novel tricyclic compounds | ABBVIE 公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-RE47221-E1 | Tricyclic compounds | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| CN-109053742-A | New tricyclic compound | ABBVIE 公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108774237-A | New tricyclic compound | ABBVIE 公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-104370909-B | Tricyclic compound | ABBVIE 公司 | 2018-09-11 | — | — | CN | disclosed |
| EP-3266786-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| CN-104370909-A | Novel tricyclic compounds | ABBOTT LAB | 2015-02-25 | — | — | CN | disclosed |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES | 2013-08-22 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102711476-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| EP-1737811-A4 | CETP INHIBITORS | MERCK & CO INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-0980359-A1 | BENZIMIDAZOLE DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050368-A1 | BENZIMIDAZOLE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TACR1 204/4885MTOR 303/4885MLYCD 2042/4885 |
| US-20160222020-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TACR1 204/4885MTOR 303/4885MLYCD 2042/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | TACR1 204/4885MTOR 303/4885MLYCD 2042/4885 |
| US-20130216497-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | TACR1 204/4885MTOR 303/4885MLYCD 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.